We spoke with Kevin Outterson, Executive Director of CARB-X and speaker at AMR Conference 2019, about the recently launched expansion of the AMR accelerator…
CARB-X has expanded its reach by adding six partners from Germany, Switzerland, Denmark and India to its network. Launched in the US by BARDA…
In Mid-February, the UKRI Cross-Council AMR Initiative hosted a parliamentary panel highlighted the importance of research to tackle AMR. The UKRI Cross-Council AMR Initiative…
German stakeholders Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel restistance-breaking antibiotics against Gram-negative…
US researchers have shown that insect-associated microbes provide their hosts with protection against infections, suggesting that insects and their microbiomes may be a rich…
According to the newly published JPI AMR Research Funding Dashboard, the 22 member countries invested around 1.8bn€ in AMR research in 2017. An extensive…
US stakeholders active in AMR have sent a letter to US congress representatives urging the need for pull incentives. The letter was published in…
CARB-X funds US-company Recida Therapeutics to accelerate further development of the LpxC program to treat gram-negative superbugs. CARB-X, a Boston University global partnership, is…
NIAID is updating its antimicrobial resistance program and is seeking public input into strategic approaches. In 2014, NIAID published Antibacterial Resistance Program: Current Status…